Wishbone team hangs out a new shingle

Share this article:
Wishbone team hangs out a new shingle
Wishbone team hangs out a new shingle

Medical agency Wishbone was acquired years ago, but the leadership team behind the shop is coming out of retirement with a new venture, dubbed Calcium.

The name is a nod to their old vehicle—bought first by Rosetta in 2010 and then absorbed into Publicis the following year—and an allusion to the brand building that they say a small shop like theirs does better.

“It's the big agency experience without the bureaucracy,” says Steven Michaelson, who serves as the shop's CEO alongside his Wishbone partners Renee Mellas (president), Judy Capano (head of strategy) and Todd Neuhaus (creative director). Apart from a few full-time administrative, studio and editorial hands, they're it.

“Everyone in the industry is tired of being forced to work within the network model, where they have to leverage people of that caliber across five or ten brands with a lot of people working under them,” said Michaelson. “We're getting back to the thing that made Wishbone successful before we grew to 80 people and spent our time managing the employees rather than the business.”

The full-service shop, based in Midtown Manhattan, has an anchor account with Cardionet, and just launched a campaign for the company's portfolio of ambulatory ECG monitoring systems. They're also doing project work on Avanir's pseudobulbar effect drug Nuedexta.

"Clients who want to take a chance with us and grow with us will get the A Team on their account," said Michaelson.

B. A. Baracus he's not, but he and his team have built a substantial business on that premise once before.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...